CRSP
Price
$34.44
Change
-$0.45 (-1.29%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
2.99B
32 days until earnings call
DNLI
Price
$12.52
Change
-$0.34 (-2.64%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
1.87B
33 days until earnings call
Ad is loading...

CRSP vs DNLI

Header iconCRSP vs DNLI Comparison
Open Charts CRSP vs DNLIBanner chart's image
CRISPR Therapeutics AG
Price$34.44
Change-$0.45 (-1.29%)
Volume$32.74K
Capitalization2.99B
Denali Therapeutics
Price$12.52
Change-$0.34 (-2.64%)
Volume$32.73K
Capitalization1.87B
CRSP vs DNLI Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. DNLI commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (CRSP: $34.89 vs. DNLI: $12.86)
Brand notoriety: CRSP and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 193% vs. DNLI: 163%
Market capitalization -- CRSP: $2.99B vs. DNLI: $1.87B
CRSP [@Biotechnology] is valued at $2.99B. DNLI’s [@Biotechnology] market capitalization is $1.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $281.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 5 bearish.
  • DNLI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +2.05% price change this week, while DNLI (@Biotechnology) price change was -6.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.53%. For the same industry, the average monthly price growth was -18.05%, and the average quarterly price growth was -19.90%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-7.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($2.99B) has a higher market cap than DNLI($1.87B). CRSP YTD gains are higher at: -11.357 vs. DNLI (-36.899). CRSP has higher annual earnings (EBITDA): -447.31M vs. DNLI (-492.89M). CRSP has more cash in the bank: 1.9B vs. DNLI (832M). DNLI has less debt than CRSP: DNLI (48.7M) vs CRSP (224M). CRSP has higher revenues than DNLI: CRSP (35M) vs DNLI (0).
CRSPDNLICRSP / DNLI
Capitalization2.99B1.87B160%
EBITDA-447.31M-492.89M91%
Gain YTD-11.357-36.89931%
P/E RatioN/AN/A-
Revenue35M0-
Total Cash1.9B832M229%
Total Debt224M48.7M460%
FUNDAMENTALS RATINGS
CRSP vs DNLI: Fundamental Ratings
CRSP
DNLI
OUTLOOK RATING
1..100
5466
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
98100
SMR RATING
1..100
9238
PRICE GROWTH RATING
1..100
8993
P/E GROWTH RATING
1..100
7098
SEASONALITY SCORE
1..100
4950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (68) in the Biotechnology industry is in the same range as DNLI (94). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

CRSP's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as DNLI (100). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (38) in the Biotechnology industry is somewhat better than the same rating for CRSP (92). This means that DNLI’s stock grew somewhat faster than CRSP’s over the last 12 months.

CRSP's Price Growth Rating (89) in the Biotechnology industry is in the same range as DNLI (93). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

CRSP's P/E Growth Rating (70) in the Biotechnology industry is in the same range as DNLI (98). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPDNLI
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 18 days ago
81%
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IIVAX22.39N/A
N/A
Transamerica Small/Mid Cap Value A
ERSGX12.24N/A
N/A
Eaton Vance Small-Cap R
MSFKX17.90N/A
N/A
MFS Total Return R6
RDWHX9.88N/A
N/A
American Funds Dvlpg Wld Gr&Inc R5E
CTOGX11.88N/A
N/A
Calamos Timpani SMID Growth R6

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+11.58%
BEAM - CRSP
72%
Closely correlated
+12.59%
RXRX - CRSP
68%
Closely correlated
+17.13%
NTLA - CRSP
64%
Loosely correlated
+12.74%
PRME - CRSP
61%
Loosely correlated
+8.70%
ABCL - CRSP
60%
Loosely correlated
+11.92%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RCKT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+12.12%
RCKT - DNLI
60%
Loosely correlated
+12.53%
BEAM - DNLI
58%
Loosely correlated
+12.59%
NTLA - DNLI
56%
Loosely correlated
+12.74%
ARWR - DNLI
56%
Loosely correlated
+18.12%
CRSP - DNLI
54%
Loosely correlated
+11.58%
More